DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

8.340 -0.080 (-0.95%)

Delayed Quote Updated: 10:19 AM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results

September 30, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences

September 02, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica (DMAC) Q2 2026 Earnings Call Transcript ↗

August 17, 2026

ReMEDy2 stroke trial nears interim analysis with 85% enrollment complete.

Via The Motley Fool

Topics Earnings

DiaMedica Therapeutics (NASDAQ:DMAC) Posts Wider Q1 Loss but Clinical Catalysts Fuel Stock Resilience ↗

May 06, 2026

Via Chartmill

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

DiaMedica Therapeutics Q2 Earnings Call Highlights ↗

August 11, 2026

DiaMedica Therapeutics (NASDAQ:DMAC) said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the...

Via MarketBeat

Topics Earnings

DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

August 10, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026

August 04, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

June 23, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program

June 16, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica (DMAC) Q4 2025 Earnings Transcript ↗

June 01, 2026

DiaMedica (DMAC) Q4 2025 Earnings Transcript

Via The Motley Fool

Topics Intellectual Property

DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026

May 27, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

May 20, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 12, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica (DMAC) Q1 2026 Earnings Transcript ↗

May 08, 2026

DiaMedica (DMAC) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Death

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

May 06, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

April 30, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

RedChip's Biotech Virtual Investor Conference Replays Now Available

April 21, 2026

Via ACCESS Newswire

RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms

April 07, 2026

Via ACCESS Newswire

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

March 30, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings ↗

March 30, 2026

DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.

Via Benzinga

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

March 23, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

March 05, 2026

From DiaMedica Therapeutics Inc

Via Business Wire

DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

February 24, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA

December 18, 2025

From DiaMedica Therapeutics Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

November 14, 2025

Via Benzinga

DiaMedica Therapeutics Inc (NASDAQ:DMAC) Reports Q3 2025 Earnings and Clinical Progress ↗

November 12, 2025

DiaMedica reports Q3 2025 results, advancing DM199 for stroke and preeclampsia. The company has a cash runway into H2 2027 to fund clinical trials.

Via Chartmill

DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

November 12, 2025

From DiaMedica Therapeutics Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.